Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication

Shawn M. McClintock, Mustafa M. Husain, Stephen R. Wisniewski, Andrew A. Nierenberg, Jonathan W. Stewart, Madhukar H. Trivedi, Ian Cook, David Morris, Diane Warden, Augustus John Rush

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Little is known about the quantity or quality of residual depressive symptoms in patients with major depressive disorder (MDD) who have responded but not remitted with antidepressant treatment. This report describes the residual symptom domains and individual depressive symptoms in a large representative sample of outpatients with nonpsychotic MDD who responded without remitting after up to 12 weeks of citalopram treatment in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Response was defined as 50% or greater reduction in baseline 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) by treatment exit, and remission as a final QIDS-SR16 of less than 6. Residual symptom domains and individual symptoms were based on the QIDS-SR16 and classified as either persisting from baseline or emerging during treatment. Most responders who did not remit endorsed approximately 5 residual symptom domains and 6 to 7 residual depressive symptoms. The most common domains were insomnia (94.6%), sad mood (70.8%), and decreased concentration (69.6%). The most common individual symptoms were midnocturnal insomnia (79.0%), sad mood (70.8%), and decreased concentration/decision making (69.6%). The most common treatment-emergent symptoms were midnocturnal insomnia (51.4%) and decreased general interest (40.0%). The most common persistent symptoms were midnocturnal insomnia (81.6%), sad mood (70.8%), and decreased concentration/decision making (70.6%). Suicidal ideation was the least common treatment-emergent symptom (0.7%) and the least common persistent residual symptom (17.1%). These findings suggest that depressed outpatients who respond by 50% without remitting to citalopram treatment have a broad range of residual symptoms. Individualized treatments are warranted to specifically address each patient's residual depressive symptoms.

Original languageEnglish (US)
Pages (from-to)180-186
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume31
Issue number2
DOIs
StatePublished - Apr 2011

Fingerprint

Antidepressive Agents
Outpatients
Sleep Initiation and Maintenance Disorders
Depression
Citalopram
Therapeutics
Major Depressive Disorder
Decision Making
Suicidal Ideation
Self Report
Equipment and Supplies

Keywords

  • D
  • depression
  • residual
  • STAR
  • symptoms
  • treatment response

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. / McClintock, Shawn M.; Husain, Mustafa M.; Wisniewski, Stephen R.; Nierenberg, Andrew A.; Stewart, Jonathan W.; Trivedi, Madhukar H.; Cook, Ian; Morris, David; Warden, Diane; Rush, Augustus John.

In: Journal of Clinical Psychopharmacology, Vol. 31, No. 2, 04.2011, p. 180-186.

Research output: Contribution to journalArticle

McClintock, Shawn M. ; Husain, Mustafa M. ; Wisniewski, Stephen R. ; Nierenberg, Andrew A. ; Stewart, Jonathan W. ; Trivedi, Madhukar H. ; Cook, Ian ; Morris, David ; Warden, Diane ; Rush, Augustus John. / Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. In: Journal of Clinical Psychopharmacology. 2011 ; Vol. 31, No. 2. pp. 180-186.
@article{d55104e053b44a0ab2a518832069490b,
title = "Residual symptoms in depressed outpatients who respond by 50{\%} but do not remit to antidepressant medication",
abstract = "Little is known about the quantity or quality of residual depressive symptoms in patients with major depressive disorder (MDD) who have responded but not remitted with antidepressant treatment. This report describes the residual symptom domains and individual depressive symptoms in a large representative sample of outpatients with nonpsychotic MDD who responded without remitting after up to 12 weeks of citalopram treatment in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Response was defined as 50{\%} or greater reduction in baseline 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) by treatment exit, and remission as a final QIDS-SR16 of less than 6. Residual symptom domains and individual symptoms were based on the QIDS-SR16 and classified as either persisting from baseline or emerging during treatment. Most responders who did not remit endorsed approximately 5 residual symptom domains and 6 to 7 residual depressive symptoms. The most common domains were insomnia (94.6{\%}), sad mood (70.8{\%}), and decreased concentration (69.6{\%}). The most common individual symptoms were midnocturnal insomnia (79.0{\%}), sad mood (70.8{\%}), and decreased concentration/decision making (69.6{\%}). The most common treatment-emergent symptoms were midnocturnal insomnia (51.4{\%}) and decreased general interest (40.0{\%}). The most common persistent symptoms were midnocturnal insomnia (81.6{\%}), sad mood (70.8{\%}), and decreased concentration/decision making (70.6{\%}). Suicidal ideation was the least common treatment-emergent symptom (0.7{\%}) and the least common persistent residual symptom (17.1{\%}). These findings suggest that depressed outpatients who respond by 50{\%} without remitting to citalopram treatment have a broad range of residual symptoms. Individualized treatments are warranted to specifically address each patient's residual depressive symptoms.",
keywords = "D, depression, residual, STAR, symptoms, treatment response",
author = "McClintock, {Shawn M.} and Husain, {Mustafa M.} and Wisniewski, {Stephen R.} and Nierenberg, {Andrew A.} and Stewart, {Jonathan W.} and Trivedi, {Madhukar H.} and Ian Cook and David Morris and Diane Warden and Rush, {Augustus John}",
year = "2011",
month = "4",
doi = "10.1097/JCP.0b013e31820ebd2c",
language = "English (US)",
volume = "31",
pages = "180--186",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication

AU - McClintock, Shawn M.

AU - Husain, Mustafa M.

AU - Wisniewski, Stephen R.

AU - Nierenberg, Andrew A.

AU - Stewart, Jonathan W.

AU - Trivedi, Madhukar H.

AU - Cook, Ian

AU - Morris, David

AU - Warden, Diane

AU - Rush, Augustus John

PY - 2011/4

Y1 - 2011/4

N2 - Little is known about the quantity or quality of residual depressive symptoms in patients with major depressive disorder (MDD) who have responded but not remitted with antidepressant treatment. This report describes the residual symptom domains and individual depressive symptoms in a large representative sample of outpatients with nonpsychotic MDD who responded without remitting after up to 12 weeks of citalopram treatment in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Response was defined as 50% or greater reduction in baseline 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) by treatment exit, and remission as a final QIDS-SR16 of less than 6. Residual symptom domains and individual symptoms were based on the QIDS-SR16 and classified as either persisting from baseline or emerging during treatment. Most responders who did not remit endorsed approximately 5 residual symptom domains and 6 to 7 residual depressive symptoms. The most common domains were insomnia (94.6%), sad mood (70.8%), and decreased concentration (69.6%). The most common individual symptoms were midnocturnal insomnia (79.0%), sad mood (70.8%), and decreased concentration/decision making (69.6%). The most common treatment-emergent symptoms were midnocturnal insomnia (51.4%) and decreased general interest (40.0%). The most common persistent symptoms were midnocturnal insomnia (81.6%), sad mood (70.8%), and decreased concentration/decision making (70.6%). Suicidal ideation was the least common treatment-emergent symptom (0.7%) and the least common persistent residual symptom (17.1%). These findings suggest that depressed outpatients who respond by 50% without remitting to citalopram treatment have a broad range of residual symptoms. Individualized treatments are warranted to specifically address each patient's residual depressive symptoms.

AB - Little is known about the quantity or quality of residual depressive symptoms in patients with major depressive disorder (MDD) who have responded but not remitted with antidepressant treatment. This report describes the residual symptom domains and individual depressive symptoms in a large representative sample of outpatients with nonpsychotic MDD who responded without remitting after up to 12 weeks of citalopram treatment in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Response was defined as 50% or greater reduction in baseline 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) by treatment exit, and remission as a final QIDS-SR16 of less than 6. Residual symptom domains and individual symptoms were based on the QIDS-SR16 and classified as either persisting from baseline or emerging during treatment. Most responders who did not remit endorsed approximately 5 residual symptom domains and 6 to 7 residual depressive symptoms. The most common domains were insomnia (94.6%), sad mood (70.8%), and decreased concentration (69.6%). The most common individual symptoms were midnocturnal insomnia (79.0%), sad mood (70.8%), and decreased concentration/decision making (69.6%). The most common treatment-emergent symptoms were midnocturnal insomnia (51.4%) and decreased general interest (40.0%). The most common persistent symptoms were midnocturnal insomnia (81.6%), sad mood (70.8%), and decreased concentration/decision making (70.6%). Suicidal ideation was the least common treatment-emergent symptom (0.7%) and the least common persistent residual symptom (17.1%). These findings suggest that depressed outpatients who respond by 50% without remitting to citalopram treatment have a broad range of residual symptoms. Individualized treatments are warranted to specifically address each patient's residual depressive symptoms.

KW - D

KW - depression

KW - residual

KW - STAR

KW - symptoms

KW - treatment response

UR - http://www.scopus.com/inward/record.url?scp=79952449206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952449206&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e31820ebd2c

DO - 10.1097/JCP.0b013e31820ebd2c

M3 - Article

VL - 31

SP - 180

EP - 186

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -